Abstract
// Xin Yan 1 , Yanting Zhu 1 , Fangwei Li 1 , Wenhua Shi 1 , Jian Wang 1 , Qingting Wang 1 , Qianqian Zhang 1 , Limin Chai 1 and Manxiang Li 1 1 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China Correspondence to: Manxiang Li, email: manxiangli@hotmail.com Keywords: PANDAR; cancer; biomarker; prognosis; meta-analysis Received: July 15, 2017 Accepted: December 04, 2017 Published: January 02, 2018 ABSTRACT Promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) has been demonstrated to be aberrantly expressed in various types of cancer and might be serve as a potential biomarker for human cancers. The present study conducted a meta-analysis to investigate whether the expression of lncRNA PANDAR was associated with prognosis and clinicopathological features in relevant cancers. 10 eligible studies with a total of 1211 patients were collected by searching the electronic bibliographic databases, the results show that high expression level of PANDAR could significantly predict shorter OS in cancer patients (HR = 2.08, 95% CI: 1.55-2.80, P < 0.001) except in patients with non-small cell lung cancer (NSCLC). There was also a significant association between high level of PANDAR and advanced TNM stage (OR = 2.80, 95% CI = 1.57-4.99, P < 0.001), positive lymph node metastasis (OR = 2.92, 95% CI = 1.92-4.45, P < 0.001), larger tumor size (OR = 1.41, 95% CI = 1.04-1.89, P = 0.03) and poor tumor differentiation (OR = 1.53, 95% CI = 1.09–2.15, P = 0.01). In conclusion, the meta-analysis results indicate that increased expression level of PANDAR was associated with unfavorable prognosis and might serve as a predictive factor for advanced clinicopathological features in various cancers.
Highlights
Cancer is a major public health problem and the second leading cause of death in the United States, besides, it is estimated that 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in 2017 [1]
The present study conducted a meta-analysis to investigate whether the expression of lncRNA PANDAR was associated with prognosis and clinicopathological features in relevant cancers. 10 eligible studies with a total of 1211 patients were collected by searching the electronic bibliographic databases, the results show that high expression level of PANDAR could significantly predict shorter overall survival (OS) in cancer patients (HR = 2.08, 95% confidence interval (CI): 1.55-2.80, P < 0.001) except in patients with non-small cell lung cancer (NSCLC)
All of studies were conducted in China and there were 9 kinds of carcinomas among them, including nonsmall cell lung cancer, colorectal cancer, clear cell renal cell carcinoma, cholangio carcinoma, renal cell carcinoma, gastric cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma and bladder cancer
Summary
Cancer is a major public health problem and the second leading cause of death in the United States, besides, it is estimated that 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in 2017 [1]. It is set to become a major cause of morbidity and mortality in the coming decades worldwide [2]. Tumor markers gradually sparked considerable attention for their striking role in identifying the tumor at an early stage when it is still localized or even before clinical symptoms appear [3]. Apart from diagnosis, biomarkers can offer physicians actionable information leading to optimal therapy and prognostication of disease progression [4]. It is urgent to seek out more markers to have a better control of cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
